Department of Gynecology, Hôpital Femme Mère Enfant, HFME, University Hospital of Lyon, Bron, France.
EMR 3738 CICLY, University Claude Bernard of Lyon 1, Lyon, France.
Eur J Contracept Reprod Health Care. 2024 Aug;29(4):163-170. doi: 10.1080/13625187.2024.2349039. Epub 2024 May 30.
OBJECTIVE(S): Management and localisation strategies to remove nonpalpable contraceptive implants may be difficult. We aimed to evaluate our imaging modalities to identify deep implant and patient outcomes related to removal.
In this retrospective study, we reviewed all cases referred to our specialised centre for nonpalpable contraceptive implants from January 2018 to August 2022.
Out of the cohort studied, 47 female subjects exhibited nonpalpable implants. The implant was nonpalpable for thirty-six patients (76,6%) immediately after the insertion whereas it was not palpable several months after the insertion for eleven patients (23.4%). Twelve patients (25.5%) had one or more failed removal attempts before referral.All 47 implants were successfully visualised ultrasound in the upper arm: 40 implants (85.1%) were located in the subdermal tissue, 4 (8.5%) were intrafascial and 3 (6.4%) were intramuscular. Depth of the implant was 4.0 mm [1.7 - 12.0]. No clinical factors were statistically associated with differences in depth or location (subdermal vs subfascial). Removal procedures were mainly under local anaesthesia in 74.5% of cases in an outpatient setting. There were two Clavien-Dindo grade 1 complications (one case of cutaneous scar dehiscence and one transient postoperative neuropathic complaint in the upper arm resolved within 3 months under analgetics).
Identification of deep implants requires following the ultrasound modality protocol. Ultrasound detection makes easy and safe implant removal. Training programs for the insertion as well as for the removal of correct and incorrect inserted implants should be continued and developed all around the world.
难以管理和定位以去除不可触及的避孕植入物。我们旨在评估我们的影像学方法,以确定与取出相关的深部植入物和患者结局。
在这项回顾性研究中,我们回顾了 2018 年 1 月至 2022 年 8 月期间向我们专门中心转诊的所有不可触及避孕植入物病例。
在所研究的队列中,47 名女性表现出不可触及的植入物。36 名患者(76.6%)在植入后立即不可触及植入物,而 11 名患者(23.4%)在植入后几个月不可触及。12 名患者(25.5%)在转诊前有一次或多次取出失败的尝试。所有 47 个植入物均在超声上臂中成功可视化:40 个植入物(85.1%)位于皮下组织,4 个(8.5%)位于筋膜内,3 个(6.4%)位于肌肉内。植入物的深度为 4.0mm[1.7-12.0]。深度或位置(皮下与筋膜下)无统计学差异的临床因素。在 74.5%的情况下,取出程序主要在局部麻醉下进行,在门诊环境下进行。有两个 Clavien-Dindo 1 级并发症(1 例皮肤疤痕裂开,1 例上臂术后短暂神经病变,在 3 个月内用止痛药解决)。
深部植入物的识别需要遵循超声模式方案。超声检测使植入物的取出变得容易和安全。应在全球范围内继续和开发正确和不正确插入植入物的插入和取出的培训计划。